Feasibility and tolerability of bevacizumab in children with primary CNS tumors

Pediatric Blood and Cancer

Volumn 54, Issue 5, 2010, Pages 681-686

  Reismüller, Bettina ^a   Azizi, Amedeo A ^a   Peyrl, Andreas ^a   Heinrich, Monika ^a   Gruber Olipitz, Mariella ^a   Luckner, Doris ^a   Rothschild, Klara Vergesslich ^a   Slavc, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse effects; Bevacizumab; Brain tumors; Children; Lymphopenia; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENOFIBRATE; TEMOZOLOMIDE; THALIDOMIDE; THYROID HORMONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; ATRIOVENTRICULAR BLOCK; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EPENDYMOMA; FEASIBILITY STUDY; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; NEPHROTIC SYNDROME; OLIGOGASTROCYTOMA; PATIENT MONITORING; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; RETROSPECTIVE STUDY; RHABDOID TUMOR; SCHOOL CHILD; SIDE EFFECT; THROMBOSIS; TREATMENT DURATION; WOUND HEALING IMPAIRMENT; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; INFANT; PATHOLOGY; SURVIVAL;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT; LYMPHOPENIA; MALE; PROTEINURIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77950506554     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22409     Document Type: Article

References (46)

1. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
3. Kabbinavar F, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712. (Pubitemid 46252465)
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (fu)/leukovorin (lv) with fu/lv alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
6. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
7. Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
9. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: Bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718. (Pubitemid 47036205)
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
11. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Calgb 90206. J Clin Oncol 2008;26:5422-5428.
12. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434. (Pubitemid 36910021)
13. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-3139. (Pubitemid 44869016)
14. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, et al. Preliminary results of the combination of bevazicumab and weekly paclitaxel in advanced melanoma. Oncology 2008;74:12-16. (Pubitemid 351915004)
15. Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-143.
16. Slongo ML, Molena B, Brunati AM, et al. Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro-Oncology 2007;9:384-392.
17. Grizzi F, Weber C, Di Ieva A. Antiangiogenic strategies in medulloblastoma: Reality or mystery. Pediatr Res 2008;63:584-590. (Pubitemid 351572230)
18. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259. (Pubitemid 46424067)
19. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas. Neurology 2008;70:779-787.
20. Kang TY, Jin T, Elinzano H, et al. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 2008;89:113-118.
21. Benesch M,Windelberg M, SausengW, et al. Compassionate use of bevacizumab (avastin(r)) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2007;19:807-813.
22. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52:791-795.
23. Kieran M, Turner C, Rubin J, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581. (Pubitemid 41697342)
24. Smith AR, Hennessy JM, Heisel-Kurth MA, et al. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer 2008;51:418-420.
25. Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 2009;25:1293-1301.
26. Bowers DC, Gargan L, Weprin BE, et al. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. J Neurosurg 2007;107:5-10.
27. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A pediatric brain tumor consortium report. Neuro-Oncology 2007;9:145-160.
28. Honda M, So G, Kaminogo M, et al. Massive intratumoral hemorrhage of ependymoma of the fourth ventricle. Childs Nerv Syst 2005;21:926-929. (Pubitemid 41403536)
29. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508. (Pubitemid 46243494)
30. Friedman HS, Prados MD,Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
31. Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-7073.
32. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729. (Pubitemid 350086473)
33. Glade-Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors:AChildren's Oncology Group Study. J Clin Oncol 2008;26:399-405. (Pubitemid 351171691)
34. Li B, Ogasawara AK, Yang R, et al. Kdr (vegf receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39:1095-1100. (Pubitemid 34620130)
35. He H, Venema VJ, Gu X, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/kdr activation of c-src. J Biol Chem 1999;274:25130-25135. (Pubitemid 129529409)
36. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogensis 2004;7:193-201.
37. Jackman DM, Kindler HJ, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-814.
38. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: Case report and literature review. Am J Kidney Dis 2007;49:E23-E29. (Pubitemid 46164815)
39. Esteve JB, Launay-Vacher V, Brocheriou I, et al. Cox-2 inhibitors and acute interstitial nephritis: Case report and review of the literature. Clin Nephrol 2005;63:385-389. (Pubitemid 40668233)
40. Mason JC, Steinberg R, Lidington EA, et al. Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a vegf receptor-2 (VEGFR2)- and protein kinase c-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin a. J Biol Chem 2004;279:41611-41618. (Pubitemid 39313604)
41. Wang JF, Milosveski V, Schramek C, et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998;157:5-12. (Pubitemid 28177487)
42. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-H576.
43. Bergh JJ, Lin HY, Lansing L, et al. Integrin alphavbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005;146:2864-2871. (Pubitemid 41002793)
44. D'Arezzo S, Incerpi S, Davis FB, et al. Rapid nongenomic effects of 3,5,3′-triiodo-L-thyronine on the intracellular pH of l-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways. Endocrinology 2004;145:5694-5703.
45. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180. (Pubitemid 41254420)
46. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.